Kempharm - Volume dana dhuwit perusahaan ZVRA

Simbol resmi perusahaan Zevra Therapeutics (ZVRA)

Zevra Therapeutics (ZVRA) develops drugs for rare neurological pathologies, where sales stability is based on constant demand. The transition to the commercialization of orphan drugs ensures sustainable growth regardless of recessions. The cash balance demonstrates current liquidity, with the value maintained at 0.19. The business relies on the specialized medicine market, offering breakthrough solutions for sleep and attention therapy.

Kempharm - Dana dhuwit perusahaan ZVRA (periode 28.04.2023 - 21.11.2026)

Rincian analitis perusahaan Zevra Therapeutics

- rega saiki lan proyeksi nilai saham:
Pambiji fundamental:Kempharm ZVRA
Produk merek Zevra Therapeutics Inc

This indicator reflects the current balance between the organization's operating income and expenses. The metric measures liquidity by assessing the business's ability to accumulate reserves or, conversely, burn capital. By analyzing the cash accumulation chart, an investor determines the company's financial stability. For Zevra Therapeutics (ZVRA), this is critical, as the niche rare disease market and regulatory risks complicate the path to stable profitability.